HealthSonix Achieves Milestone of Over 107,000 Sound Pressure Wave Treatments
Posted on: Thursday, 14 September 2006, 09:00 CDT
HealthSonix, Inc. (PINKSHEETS: HSXI) announced the successful completion of over 107,000 of its Sound Pressure Wave treatments which have proven successful in reducing the pain associated with arthritis and other diseases, improving physical function and reducing stiffness in patients with arthritis. Dr. David Venturi, Medical Director of HealthSonix, Inc., commented, "Sound pressure waves stimulate the mechanoreceptors located in the skin, which in turn, block pain signals to the brain. The end effect is a reduction in pain allowing patients undergoing the AquaSonix therapy to progressively increase their exercise regimen in the pool. Successful completion of over 100,000 treatments marks a significant milestone in implementing our business plan and expanding our treatment regimen to more and more arthritis patients throughout North America."
The Company began research and development of its patent-pending medical technology in 2001 and began with clinical research and trials in 2003. Since 2001, over five million dollars has been invested in research, clinical trials and regulatory compliance. AquaSonix Therapy is currently offered at 17 locations in North America. The FDA-registered AquaSonix medical device is at the core of this new therapy program. The treatment combines sound pressure waves with individualized low impact exercise programs in warm water therapy pools. The program is consistent with the published guidelines of the American College of Rheumatology (ACR), which recommend non-drug therapies as the foundation of the treatment of patients with osteoarthritis.
HealthSonix, Inc. (PINKSHEETS: HSXI) is a publicly traded medical technology company. The Company's core offerings are based on proprietary, patent-pending medical technologies that use sound pressure waves to stimulate the mechanoreceptors to inhibit arthritis-related pain signals. Precisely formatted low frequency sound pressure waves are 80% effective in treating the pain of many diseases, particularly arthritis. All treatments and products are safe, non-invasive, drug free, and have no known side effects.
More information regarding HealthSonix and its products and services can be found at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact: Dieter Doederlein 1-877-622-2121 http://www.healthsonix.com
SOURCE: HealthSonix, Inc.
Source: MARKET WIRE
Related Articles
- BRIGHT Results Show Less Pain and Higher Patient Satisfaction With Betaseron(R) Than With Rebif(R)
- 'Arthritis Without Pain' - The Long-Awaited Breakthrough for Arthritis Pain
- Integrated Pain Solutions Selects Heartland Therapy Provider Network, a Division of HCR Manor Care, to Serve As Integral Member of Priviledged Provider Network
- Companion Technologies Adds Web Interface for Medical Patient Statements
- Sound Medication Therapy Management Programs Described By Health Care and Business Leaders
- Juvenile Arthritis Makes Childhood Activities Painful for Young Patients
- Sound Medical Imaging First in New Hampshire to Acquire Revolutionary Zone Sonography(TM) Ultrasound Technology
- Cephalon Files New Drug Application for OraVescent(R) Fentanyl for the Management of Breakthrough Pain in Cancer Patients
- Emerging Strategies in the Prevention of Venous Thromboembolism in Hospitalized Medical Patients*
- Dalteparin Reduced Venous Thromboembolic Events Without Increased Bleeding in Acutely Ill Medical Patients/COMMENTARY
 |
 |
User Comments (0)
RSS Feeds